Click here to close now.




















Welcome!

News Feed Item

PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012

NEW YORK, Feb. 12, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
http://www.reportlinker.com/p02013603/PharmaSphere-Pharmaceutical-and-Healthcare-Deal-Trends-in-Latin-America-2008---2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012

Summary

"PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012" report provides an in-depth understanding of the key deals that took place in the region during the last decade. The type of deals covered in the report include Mergers & Acquisitions (M&A), Licensing and Collaboration & Partnerships.

The report also provides understanding on the regional differences in the deal making activity to that of the global trends and key trends are outlined with insight on drivers such as regulatory policy, macro-economic and industry factors as well as market access challenges. Case studies including the top five deals in value among Mergers & Acquisition, Licensing and Collaboration & Partnerships are strategically analyzed to provide comprehensive understanding on areas such as structure and status of the deal vis a vis the overall corporate strategy.

Highlights

Key Questions Answered

- How are the main deal categories faring among top countries in the Latin America region over the past five years?
- What are the primary reasons for increased activity in strategic deals by leading pharmaceutical companies in LATAM region?
- What are the key trends, and strategies involved in M&As, licensing deals, and collaboration agreements entered into by leading pharmaceutical and healthcare companies in the Latin American region?
- What strategies are the most successful companies pursuing to gain and maintain their market leading position?
- Which are the key companies that are potential targets of acquisitions?

Scope

- Report provides in-depth understanding of the key pharmaceutical and healthcare deals that took place in the LATAM region during the past five years. Furthermore, key deals are discussed from a domestic and global point of view.
- Current regulatory framework in various markets in LATAM including recent and/or ongoing developments that are expected to impact or influencing the industry are discussed. In-depth commentary on four countries in the region are included.
- Highly Insightful analyses on the deal making terms, strategic implications and synergies of recent deals activity in the LATAM pharmaceutical industry.
- Collaboration & Acquisition Strategies: Exhaustive discussion on the strategic implications and synergies of recent M&A and partnering activities. Case Studies of five deals are included in each deal category.
- Expert Insights on the corporate strategies of various drug companies seeking a competitive advantage in the pharmaceutical market place.
- Five major regional companies are profiled providing an in-depth analysis on their individual deal making strategies.
- Number of Case Studies on top deal making activities shedding light on rationale and strategy. Potential targets for acquisitions in the region are also identified.

Reasons to buy

- Understand the primary drivers behind major deal initiatives in the LATAM region.
- Analyze the structure of the deals and gain insight on the various factors considered when structuring deal terms in strategic acquisitions, mergers, collaborations, and licensing.
- Identify rationale behind potential takeover targets and partners, thereby maximizing your opportunities for consolidation, investment, and strategic partnerships in the Asia Pacific region.
- Use this information as an independent source for your due diligence and transaction strategy.
1 Table of Contents
1 Table of Contents 7
1.1 List of Tables 10
1.2 List of Figures 12
2 Introduction 14
2.1 Report Scope 14
2.1.1 Key Questions Answered 14
2.1.2 Key Benefits 15
2.1.3 Upcoming Related Reports 15
3 Historical Dealmaking Trends 16
3.1 Overview 16
3.2 Leading Deal Drivers 17
3.2.1 Dampening Global Pharmaceutical Markets 17
3.2.2 Intellectual Property Issues and Rising Competition 18
3.2.3 Universal Healthcare Access, Primary Healthcare, and Health Insurance 19
3.2.4 Increasing Consolidation 20
3.3 Overall Deals in Review 21
3.3.1 Review by Deal Type 21
4 Regional Country Profiles 28
4.1 Brazil 28
4.1.1 Overview 28
4.1.2 Top Deals by Value and Volume 29
4.1.3 Market Dynamics 31
4.2 Mexico 34
4.2.1 Overview 34
4.2.2 Top Deals by Value and Volume 35
4.2.3 Market Dynamics 37
4.3 Argentina 41
4.3.1 Overview 41
4.3.2 Top Deals by Value and Volume 42
4.3.3 Market Dynamics 44
4.4 Venezuela 48
4.4.1 Overview 48
4.4.2 Top Deals by Value and Volume 49
4.4.3 Market Dynamics 51
5 Mergers and Acquisitions 55
5.1 Overview 55
5.2 Case Studies 57
5.2.1 UnitedHealth Group Acquires Amil Participações 57
5.2.2 Hypermarcas Acquires Mantecorp Indústria Química e Farmacêutica 59
5.2.3 Hypermarcas Acquires Laboratório Neo Química 60
5.2.4 Acquisition of Lafrancol (Colombia) by Recalcine (Chile) 61
5.2.5 Sanofi Aventis Acquires Medley Indústria Farmacêutica 62
6 Licensing Agreements 64
6.1 Overview 64
6.2 Case Studies 66
6.2.1 FBM Indústria Farmacêutica (FBM Farma) Enters into Licensing Agreement with Ampio Pharmaceuticals 66
6.2.2 FAES Farma and Pfizer Expand Bilastine License Agreement 67
6.2.3 CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm 68
6.2.4 Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma 70
6.2.5 Oxford Nutrascience Enters into Licensing Agreement with Aché Laboratórios 71
7 Collaborations and Partnerships 73
7.1 Overview 73
7.2 Case Studies 75
7.2.1 Pfizer Enters into an Agreement with Laboratório Teuto Brasileiro 75
7.2.2 Avesthagen Forms a Joint Venture with Uxmal 77
7.2.3 Baxter International Enters into Agreement with Hemobras for Recombinant Factor VIII (rFVIII) Hemophilia Treatment 78
7.2.4 Cristalia, Biolab, Eurofarma, and Libbs Enter into Joint Venture for Biological Medicines 80
7.2.5 Aché , Uniao Química Farmacêutica, Hypermarcas, and EMS Laboratories Set Up a Joint Venture 81
8 Deal Strategy of Major LATAM Companies 83
8.1 Amil Participações S.A. 83
8.1.1 Recent Deals: M&As, Licensing, and Partnerships 83
8.1.2 Overall Deal Strategy 84
8.2 Hypermarcas 85
8.2.1 Recent Deals: M&As, Licensing, and Partnerships 85
8.2.2 Overall Deals Strategy 86
8.3 Grupo Casa Saba 87
8.3.1 Recent Deals: M&As, Licensing, and Partnerships 87
8.3.2 Overall Deals Strategy 87
8.4 Genomma Lab Internacional 88
8.4.1 Recent Deals: M&As, Licensing, and Partnerships 88
8.4.2 Overall Deals Strategy 88
8.5 CFR Pharmaceuticals 89
8.5.1 Recent Deals: M&As, Licensing, and Partnerships 89
8.5.2 Overall Deals Strategy 90
9 Future Outlook 91
9.1 Overview 91
9.2 Deal-Making Trends 91
9.2.1 Mergers and Acquisitions 91
9.2.2 Licensing and Partnership Deals to Rise in Quest for Portfolio and Pipeline Growth 93
9.2.3 Market Access Challenges will Impact Deal Activity 93
10 Appendix 95
10.1 Bibliography 95
10.2 Abbreviations 97
10.3 About the Author 100
10.3.1 Industry Analyst 100
10.4 Director of Healthcare Industry Dynamics 100
10.5 Global Head of Healthcare 101
10.6 About the Industry Dynamics Team 101
10.7 About GlobalData 101
10.8 Disclaimer 102

1.1 List of Tables

Table 1: Overview of Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Brazil, 2008-2012 29
Table 2: Market Share Split of Pharma Firms in Brazil 33
Table 3: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Mexico, 2008-2012 35
Table 4: Pharmaceutical Market, Mexico, Forecast ($bn), 2011-2020 38
Table 5: Top 10 Pharma Firms in Mexico Revenue-Wise 39
Table 6: Top Healthcare Distribution Firms in Mexico Revenue-Wise 40
Table 7: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Argentina, 2008-2012 42
Table 8: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020 45
Table 9: Top 10 Pharma Firms in Argentina, Revenue-Wise 46
Table 10: Overview of the Top M&As, Licensing agreements, and Collaboration and Partnership Deals in Venezuela, 2008-2012 49
Table 11: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 52
Table 12: Top 10 M&A Deals by Value, LATAM Region, 2008-2012 56
Table 13: UnitedHealth Acquires Amil Participações 57
Table 14: Hypermarcas Acquires Mantecorp 59
Table 15: Hypermarcas Acquires Laboratório Neo Química Comércio e Indústria 60
Table 16: Recalcine Acquires Lafrancol 61
Table 17: Sanofi Aventis Acquires Medley Indústria Farmacêutica 62
Table 18: Major Licensing Deals, LATAM Region, 2008-2012 64
Table 19: FBM Farma Indústria Farmacêutica Licenses Zertane from Ampio Pharmaceuticals 66
Table 20: Pfizer and Faes Farma in Licensing Deal for Bilastine 67
Table 21: CEL-SCI Enters into Licensing Agreement with IDC-GP Pharm 68
Table 22: Vanda Pharma Enters into Licensing Agreement with Biotoscana Farma 70
Table 23: Oxford Nutrascience Enters into Licensing Agreement with Ache Laboratórios 71
Table 24: Top 10 Collaboration and Partnership Deals in the LATAM Region, 2008-2012 74
Table 25: Pfizer Enters Into An Agreement With Laboratório Teuto Brasileiro 75
Table 26: Avesthagen Enters into Agreement with Uxmal 77
Table 27: Baxter International Enters Into Agreement With Hemobras 78
Table 28: Cristalia, Biolab, Eurofarma and Libbs Enter into Joint Venture 80
Table 29: Aché , Uniao Química Farmacêutica , Hypermarcas, and EMS Laboratories Set Up a Joint Venture 81
Table 30: Amil Participações ' Recent Deals Activity 83
Table 31: Hypermarcas' Recent Deals Activity 85
Table 32: Grupo Casa Saba's Recent Deals Activity 87
Table 33: Genomma Lab Internacional's Recent Deals Activity 88
Table 34: CFR Pharmaceuticals' Recent Deals Activity 89

List of Figures

Figure 1: Foreign Direct Investment Flow, LATAM Region, 2011-2012 17
Figure 2: Research and Development Spending of PhRMA Members, 2005-2012 18
Figure 3: Trend in M&A Deal Volume, LATAM Region, 2008-2012 22
Figure 4: Trend in M&A Deal Values, LATAM Region, 2008-2012 23
Figure 5: Volume of Licensing Deals, LATAM Region, 2008-2012 24
Figure 6: Trend in Licensing Deal Values, LATAM Region, 2008-2012 25
Figure 7: Trend in Collaboration and Partnership Deal Volumes, LATAM Region, 2009-2012 26
Figure 8: Trend in Collaboration and Partnership Deal Values, LATAM Region, 2009-2012 27
Figure 9: Trends in Deal Volume in Brazil, 2008-2012 30
Figure 10: Volume of Deal Types in Brazil, 2008-2012 31
Figure 11: Pharmaceutical Market, Brazil, Revenue ($bn), Forecast, 2013-2020 32
Figure 12: Trends in Deal Volume in Mexico, 2008-2012 36
Figure 13: Volume of Deal Types in Mexico, 2008-2012 37
Figure 14: Trend in Market Forecast in Mexico, 2011-2020 38
Figure 15: Trends in Deal Volume in Argentina, 2008-2012 43
Figure 16: Volume of Deal Types in Argentina, 2008-2012 44
Figure 17: Pharmaceutical Market, Argentina, Revenue ($bn), Forecast, 2013-2020 45
Figure 18: Trends in Deal Volume in Venezuela, 2009-2012 50
Figure 19: Trends in Volume of Deal Types in Venezuela, 2009-2012 50
Figure 20: Pharmaceutical Market ($bn), Venezuela, Forecast, 2012-2020 52
Figure 21: Number of M&A Deals in Major Countries, LATAM Region, 2008-2012 57
Figure 22: Split in Volume of Licensing Deals among Drug Development Phases, LATAM Region, 2008-2012 65

To order this report: PharmaSphere: Pharmaceutical and Healthcare Deal Trends in Latin America: 2008 - 2012
http://www.reportlinker.com/p02013603/PharmaSphere-Pharmaceutical-and-Healthcare-Deal-Trends-in-Latin-America-2008---2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Any Ops team trying to support a company in today’s cloud-connected world knows that a new way of thinking is required – one just as dramatic than the shift from Ops to DevOps. The diversity of modern operations requires teams to focus their impact on breadth vs. depth. In his session at DevOps Summit, Adam Serediuk, Director of Operations at xMatters, Inc., will discuss the strategic requirements of evolving from Ops to DevOps, and why modern Operations has begun leveraging the “NoOps” approa...
SYS-CON Events announced today that IceWarp will exhibit at the 17th International Cloud Expo®, which will take place on November 3–5, 2015, at the Santa Clara Convention Center in Santa Clara, CA. IceWarp, the leader of cloud and on-premise messaging, delivers secured email, chat, documents, conferencing and collaboration to today's mobile workforce, all in one unified interface
The Internet of Things (IoT) is about the digitization of physical assets including sensors, devices, machines, gateways, and the network. It creates possibilities for significant value creation and new revenue generating business models via data democratization and ubiquitous analytics across IoT networks. The explosion of data in all forms in IoT requires a more robust and broader lens in order to enable smarter timely actions and better outcomes. Business operations become the key driver of I...
Organizations from small to large are increasingly adopting cloud solutions to deliver essential business services at a much lower cost. According to cyber security experts, the frequency and severity of cyber-attacks are on the rise, causing alarm to businesses and customers across a variety of industries. To defend against exploits like these, a company must adopt a comprehensive security defense strategy that is designed for their business. In 2015, organizations such as United Airlines, Sony...
Skeuomorphism usually means retaining existing design cues in something new that doesn’t actually need them. However, the concept of skeuomorphism can be thought of as relating more broadly to applying existing patterns to new technologies that, in fact, cry out for new approaches. In his session at DevOps Summit, Gordon Haff, Senior Cloud Strategy Marketing and Evangelism Manager at Red Hat, discussed why containers should be paired with new architectural practices such as microservices rathe...
With the proliferation of connected devices underpinning new Internet of Things systems, Brandon Schulz, Director of Luxoft IoT – Retail, will be looking at the transformation of the retail customer experience in brick and mortar stores in his session at @ThingsExpo. Questions he will address include: Will beacons drop to the wayside like QR codes, or be a proximity-based profit driver? How will the customer experience change in stores of all types when everything can be instrumented and a...
It’s been proven time and time again that in tech, diversity drives greater innovation, better team productivity and greater profits and market share. So what can we do in our DevOps teams to embrace diversity and help transform the culture of development and operations into a true “DevOps” team? In her session at DevOps Summit, Stefana Muller, Director, Product Management – Continuous Delivery at CA Technologies, answered that question citing examples, showing how to create opportunities for ...
As more and more data is generated from a variety of connected devices, the need to get insights from this data and predict future behavior and trends is increasingly essential for businesses. Real-time stream processing is needed in a variety of different industries such as Manufacturing, Oil and Gas, Automobile, Finance, Online Retail, Smart Grids, and Healthcare. Azure Stream Analytics is a fully managed distributed stream computation service that provides low latency, scalable processing of ...
Everyone talks about continuous integration and continuous delivery but those are just two ends of the pipeline. In the middle of DevOps is continuous testing (CT), and many organizations are struggling to implement continuous testing effectively. After all, without continuous testing there is no delivery. And Lab-As-A-Service (LaaS) enhances the CT with dynamic on-demand self-serve test topologies. CT together with LAAS make a powerful combination that perfectly serves complex software developm...
WebRTC has had a real tough three or four years, and so have those working with it. Only a few short years ago, the development world were excited about WebRTC and proclaiming how awesome it was. You might have played with the technology a couple of years ago, only to find the extra infrastructure requirements were painful to implement and poorly documented. This probably left a bitter taste in your mouth, especially when things went wrong.
As more intelligent IoT applications shift into gear, they’re merging into the ever-increasing traffic flow of the Internet. It won’t be long before we experience bottlenecks, as IoT traffic peaks during rush hours. Organizations that are unprepared will find themselves by the side of the road unable to cross back into the fast lane. As billions of new devices begin to communicate and exchange data – will your infrastructure be scalable enough to handle this new interconnected world?
In today's digital world, change is the one constant. Disruptive innovations like cloud, mobility, social media, and the Internet of Things have reshaped the market and set new standards in customer expectations. To remain competitive, businesses must tap the potential of emerging technologies and markets through the rapid release of new products and services. However, the rigid and siloed structures of traditional IT platforms and processes are slowing them down – resulting in lengthy delivery ...
In their Live Hack” presentation at 17th Cloud Expo, Stephen Coty and Paul Fletcher, Chief Security Evangelists at Alert Logic, will provide the audience with a chance to see a live demonstration of the common tools cyber attackers use to attack cloud and traditional IT systems. This “Live Hack” uses open source attack tools that are free and available for download by anybody. Attendees will learn where to find and how to operate these tools for the purpose of testing their own IT infrastructu...
Whether you like it or not, DevOps is on track for a remarkable alliance with security. The SEC didn’t approve the merger. And your boss hasn’t heard anything about it. Yet, this unruly triumvirate will soon dominate and deliver DevSecOps faster, cheaper, better, and on an unprecedented scale. In his session at DevOps Summit, Frank Bunger, VP of Customer Success at ScriptRock, will discuss how this cathartic moment will propel the DevOps movement from such stuff as dreams are made on to a prac...
Too often with compelling new technologies market participants become overly enamored with that attractiveness of the technology and neglect underlying business drivers. This tendency, what some call the “newest shiny object syndrome,” is understandable given that virtually all of us are heavily engaged in technology. But it is also mistaken. Without concrete business cases driving its deployment, IoT, like many other technologies before it, will fade into obscurity.